Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Metabolism: Clinical and Experimental|December 15, 2007
Nateglinide prevents fatty liver through up-regulation of lipid oxidation pathway in Goto-Kakizaki rats on a high-fat dietTomoyuki Mine, Kyoko Miura, Toshifumi Kajioka, et al.
British Journal of Clinical Pharmacology|October 29, 2019
AJM300, a novel oral antagonist of α4-integrin, sustains an increase in circulating lymphocytes: A randomised controlled trial in healthy male subjectsHiroyuki Fukase, Toshifumi Kajioka, Ichiro Oikawa, et al.
Clinical Drug Investigation|January 23, 2020
Food Effect on a Single High Dose of Carotegrast Methyl, an Oral Antagonist of α4-Integrin, in Healthy Male Subjects: A Randomised, Placebo-Controlled, Double-Blind StudyHiroyuki Fukase, Toshifumi Kajioka, Ichiro Oikawa, et al.
The Journal of Biological Chemistry|November 1, 2005
GSK-3beta directly phosphorylates and activates MARK2/PAR-1Shinichi Kosuga, Etsu Tashiro, Toshifumi Kajioka, et al.
Crohn'S & Colitis 360|November 29, 2023
Questionnaire Survey for Inflammatory Bowel Disease Patients in Japan; A Web-Based Japan, Crohn's Disease, Ulcerative Colitis, Patients SurveyTakayuki Matsumoto, Keita Imai, Yuki Goda, et al.
Crohn'S & Colitis 360|May 9, 2025
Questionnaire Survey of Japanese Patients With Inflammatory Bowel Disease and Physicians on Shared Decision-Making in Advanced Therapy: A Web-Based PAIR SurveyFumihito Hirai, Takayuki Matsumoto, Keita Imai, et al.
The Lancet. Gastroenterology & Hepatology|April 2, 2022
AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 studyKatsuyoshi Matsuoka, Mamoru Watanabe, Toshihide Ohmori, et al.
Pageof 1